Immunovant, Inc. - Common Stock (NQ:IMVT)

22.98 -0.67 (-2.83%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Immunovant, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

September 26, 2023

Pre-market stock movers are among the biggest topics worth checking out on Tuesday and we have the latest news for investors!

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

September 18, 2023

Via Benzinga

Where Immunovant Stands With Analysts ↗

September 18, 2023

Via Benzinga

If You Invested $1000 In Vivek Ramaswamy-Founded Roivant When He Declared Presidential Bid, Here's How Much You'd Have Now ↗

August 25, 2023

Roivant stock has outperformed the broader market and the biotech sector this year, mirroring the rise in the fortunes of its founder Vivek Ramaswamy.

Via Benzinga

What 11 Analyst Ratings Have To Say About Immunovant ↗

August 16, 2023

Via Benzinga

9 Analysts Have This to Say About Immunovant ↗

July 18, 2023

Via Benzinga

HC Wainwright & Co. Maintains Buy Rating for Immunovant: Here's What You Need To Know ↗

May 23, 2023

Via Benzinga

Immunovant Inc. (NASDAQ: IMVT) is a Stock Spotlight on 5/23

May 23, 2023

Via Investor Brand Network

Immunovant's FcRn Strategy Gains Momentum: Analysts View ADHERE Study as De-Risking Factor for CIDP Clinical Development ↗

July 18, 2023

Monday, Argenx SE (NASDAQ: ARGX) reported topline results from the ADHERE study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with chronic inflammatory demyelinating...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

July 17, 2023

It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday!

Via InvestorPlace

Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

July 17, 2023

U.S. stock futures traded mixed this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Analyst Expectations for Immunovant's Future ↗

May 23, 2023

Via Benzinga

Recap: Immunovant Q4 Earnings ↗

May 22, 2023

Via Benzinga

Analyst Expectations for Immunovant's Future ↗

April 25, 2023

Via Benzinga

7 Analysts Have This to Say About Immunovant ↗

March 30, 2023

Via Benzinga

Immunovant Inc. (NASDAQ: IMVT) is a Stock Spotlight on 3/24

March 24, 2023

Via Investor Brand Network

Analyst Boosts Immunovant Price Target After Updated Pipeline Realignment ↗

March 20, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023 ↗

May 01, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023 ↗

April 25, 2023

Via Benzinga

Analyst Expectations for Immunovant's Future ↗

February 07, 2023

Via Benzinga

What 6 Analyst Ratings Have To Say About Immunovant ↗

November 08, 2022

Within the last quarter, Immunovant (NASDAQ:IMVT) has observed the following analyst ratings:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023 ↗

March 31, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023 ↗

March 30, 2023

Via Benzinga

Where Immunovant Stands With Analysts ↗

November 07, 2022

Immunovant (NASDAQ:IMVT) has observed the following analyst ratings within the last quarter:

Via Benzinga

Immunovant Could Potentially Be An M&A Target, Writes Analyst ↗

February 15, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2023 ↗

February 15, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 13, 2023 ↗

February 13, 2023

Via Benzinga

Universal Health Services, Madrigal Pharmaceuticals And These Overbought Majors In The Healthcare Sector ↗

December 23, 2022

The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

6 Analysts Have This to Say About Immunovant ↗

November 08, 2022

Over the past 3 months, 6 analysts have published their opinion on Immunovant (NASDAQ:IMVT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th

November 07, 2022

From Immunovant Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.